+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

mRNA Vaccines - Global Market Trajectory & Analytics

  • ID: 5303827
  • Report
  • March 2021
  • Region: Global
  • 134 pages
  • Global Industry Analysts, Inc
1 of 2
Global mRNA Vaccines Market to Reach $30.5 Billion by 2027

Amid the COVID-19 crisis, the global market for mRNA Vaccines estimated at US$ 31.9 Billion in the year 2021, is projected to reach a size of US$ 30.5 Billion by 2027, displaying at a CAGR of -0.7% over the analysis period 2021-2027. COVID-19 Vaccine, one of the segments analyzed in the report, is projected to record a -5.9% CAGR and shrink to a market size of approximately US$ 22.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the cancer vaccine segment is projected to spiral at 166.7% CAGR for the next 6-year period.

The U.S. Market is Estimated at $14.7 Billion, While Asia-Pacific is Forecast to Grow at 12.8% CAGR

mRNA Vaccines market in the U.S. is estimated at US$ 14.7 Billion in the year 2021. Asia-Pacific (excluding China) is forecast to reach a projected market size of US$ 3.6 Billion by the year 2027 trailing a CAGR of 12.8% over the analysis period 2021 to 2027. Among the other noteworthy geographic markets are China and Rest of World (includes Latin America, Middle East and Africa), each forecast to grow at 10% and 4.2% respectively over the 2021-2027 period.

Select Competitors (Total 100 Featured):
  • Arcturus Therapeutics, Inc.
  • Argos Therapeutics, Inc.
  • BioNTech SE
  • CureVac AG
  • eTheRNA
  • ethris GmbH
  • GlaxoSmithKline PLC
  • Moderna Therapeutics Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics Inc.
  • Translate Bio Inc.
Note: Product cover images may vary from those shown
2 of 2
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Global Competitor Market Shares
  • mRNA Vaccines and Therapeutics Competitor Market Share Scenario Worldwide (in %): E
  • Global Competitor Market Shares by Segment
  • Standardization of Cancer Treatment (Type) Global Competitor Market Share Positioning for 2020 & 2027
  • Infection Disease Treatment (Type) Market Share Breakdown of Key Players: 2020 & 2027
  • Infection Prevention (Type) Competitor Revenue Share (in %): 2020 & 2027
  • Individualized Cancer Treatment (Type) Market Share Shift by Company: 2020 & 2027
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Current & Future Analysis for mRNA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
  • TABLE 2: World 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021, 2021 & 2027
  • TABLE 3: World Current & Future Analysis for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
  • TABLE 4: World 6-Year Perspective for Covid-19 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021, 2021 & 2027
  • TABLE 5: World Current & Future Analysis for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
  • TABLE 6: World 6-Year Perspective for Cancer Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021, 2021 & 2027
  • TABLE 7: World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
  • TABLE 8: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021, 2021 & 2027
  • TABLE 9: World Historic Review for mRNA Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • TABLE 10: World Historic Review for Covid-19 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • TABLE 11: World Historic Review for Cancer Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • TABLE 12: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
III. MARKET ANALYSIS
  • UNITED STATES
  • Market Facts & Figures
  • US mRNA Vaccines and Therapeutics Market Share (in %) by Company: 2020 & 2027
  • Standardization of Cancer Treatment (Type) Market Share Analysis (in %) of Leading Players in the US for 2020 & 2027
  • Infection Disease Treatment (Type) Competitor Revenue Share (in %) in the US: 2020 & 2027
  • Infection Prevention (Type) Market Share Breakdown (in %) of Major Players in the US: 2020 & 2027
  • Individualized Cancer Treatment (Type) Market in the US: Percentage Breakdown of Revenues by Company for 2020 & 2027
  • Market Analytics
  • TABLE 13: USA Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 14: USA 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 15: USA Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • CANADA
  • TABLE 16: Canada Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 17: Canada 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 18: Canada Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • JAPAN
  • TABLE 19: Japan Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 20: Japan 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 21: Japan Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • CHINA
  • TABLE 22: China Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 23: China 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 24: China Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • EUROPE
  • Market Facts & Figures
  • European mRNA Vaccines and Therapeutics Market: Competitor Market Share Scenario (in %) for 2020 & 2027
  • Standardization of Cancer Treatment (Type) Market Share (in %) by Company in Europe: 2020 & 2027
  • Infection Disease Treatment (Type) Market Share (in %) of Major Players in Europe: 2020 & 2027
  • Infection Prevention (Type) Competitor Market Share Analysis (in %) in Europe: 2020 & 2027
  • Individualized Cancer Treatment (Type) Market in Europe: Competitor Revenue Share Shift (in %) for 2020 & 2027
  • Market Analytics
  • TABLE 25: Europe Current & Future Analysis for mRNA Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2027 and % CAGR
  • TABLE 26: Europe 6-Year Perspective for mRNA Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021, 2021 & 2027
  • TABLE 27: Europe Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 28: Europe 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 29: Europe Historic Review for mRNA Vaccines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • TABLE 30: Europe Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • FRANCE
  • TABLE 31: France Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 32: France 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 33: France Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • GERMANY
  • TABLE 34: Germany Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 35: Germany 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 36: Germany Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • ITALY
  • TABLE 37: Italy Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 38: Italy 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 39: Italy Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • UNITED KINGDOM
  • TABLE 40: UK Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 41: UK 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 42: UK Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • REST OF EUROPE
  • TABLE 43: Rest of Europe Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 44: Rest of Europe 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 45: Rest of Europe Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • ASIA-PACIFIC
  • TABLE 46: Asia-Pacific Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 47: Asia-Pacific 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 48: Asia-Pacific Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
  • REST OF WORLD
  • TABLE 49: Rest of World Current & Future Analysis for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2021 through 2027 and % CAGR
  • TABLE 50: Rest of World 6-Year Perspective for mRNA Vaccines by Indication - Percentage Breakdown of Value Sales for Covid-19 Vaccine, Cancer Vaccine and Other Indications for the Years 2021, 2021 & 2027
  • TABLE 51: Rest of World Historic Review for mRNA Vaccines by Indication - Covid-19 Vaccine, Cancer Vaccine and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2021 through 2020 and % CAGR
IV. COMPETITION
  • Total Companies Profiled: 42
Note: Product cover images may vary from those shown
Adroll
adroll